Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...
Knox Henderson | February 1, 2024 |

NetraMark Holdings, bridging an important pharmaceutical industry gap

NetraMark Holdings is a tech company, looking to identify and fill current gaps in the pharmaceutical industry. The Toronto-based company offers its proprietary algorithms to change the way in which Artificial Intelligence is used in the field, uncovering insights fro...
Simon Druker | April 27, 2023 |

Medcolcanna Prepares For Recurring Commercial Shipments

An Operational Update for 2021 as The Company Prepares for Recurring Shipments Medcolcanna Organics Inc. (NEO: MCCN), a leading Colombian and globally integrated cannabis company, is providing the following corporate update. Key highlights include: Capacity &...
Featured Submission | January 25, 2021 |

Shaping the Future of Medicine by Delivering Regenerative Medicines

(Click image to play video) Envision a chest pain that feels like the most severe form of heartburn you ever experienced before. This is one of the main symptoms of ischemia – a disease which millions of people around the globe live with every day. Treati...
Dave Jackson | December 8, 2020 |

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

(Image via Lexaria Bioscience Corp.) There’s no shortage of excitement over potential COVID-19 vaccines. Just looking at the response to news around these developments is evidence of that, and one Company is working on a transformative, patented tech...
Stockhouse Editorial | December 1, 2020 |

CureVac, BioNTech, Valeo Pharma: Where is there still potential?

The race for vaccines against Covid-19 is fierce. Every day there are new water level reports - from setbacks to breakthroughs, everything is there. The Tübingen-based Company CureVac ( NASDAQ: CVAC ) recently started its phase study IIa in Peru and Panama. Around 700 people...
Nico Popp | October 16, 2020 |

BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?

When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the Corona Virus, people around ...
Mario Hose | September 23, 2020 |

BioNTech, CureVac, Valeo Pharma - Growth after capital injection

Anyone working in the medical sector knows that the development of therapies and products usually costs a lot of time and especially a lot of money. In the race against the spread of the current Corona pandemic, there are major changes in the industry, because whoever comes to...
Mario Hose | September 11, 2020 |

BioNTech, CureVac, Valeo Pharma - COVID-19 wakes up the industry

In the past, people have accepted that it usually takes about ten years to get a vaccine on the market. Careful testing with proof of success is required for a preparation to receive approvals. Since COVID-19, the pressure to develop has increased dramatically and also the pot...
Mario Hose | September 1, 2020 |
1 2 3 4 5 6